Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 619,400 shares, a growth of 747.3% from the June 30th total of 73,100 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is presently 0.2 days. Approximately 6.0% of the company’s stock are short sold.

Conduit Pharmaceuticals Trading Down 5.3 %

Shares of CDT stock traded down $0.01 during trading on Thursday, reaching $0.25. The company’s stock had a trading volume of 1,797,773 shares, compared to its average volume of 1,240,218. The stock’s 50-day moving average price is $1.65 and its 200 day moving average price is $2.63. Conduit Pharmaceuticals has a 1-year low of $0.21 and a 1-year high of $25.00.

Conduit Pharmaceuticals (NASDAQ:CDT) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.05) earnings per share for the quarter.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.